What does this video actually claim?
@alexusdevon shows how different websites list varying side effects for GLP-1 medications like Wegovy. She suggests this inconsistency is "crazy" and implies patients get conflicting information depending on their source.
The video doesn't specify which sites she compared or which exact side effects differed. Without seeing her specific examples, we can't verify her particular findings. But her broader point about inconsistent health information online deserves examination.
Do different sites really list different side effects?
Yes, but context matters enormously. The FDA's official Wegovy prescribing information lists side effects occurring in 5% or more of trial participants: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dyspepsia (9%), dizziness (8%), abdominal distension (7%), eructation (7%), hypoglycemia (6%), and flatulence (6%).
Consumer websites often cherry-pick from this data. Some focus on common but mild effects like nausea. Others emphasize rare but serious risks like pancreatitis or gallbladder problems.
Medical databases like UpToDate include detailed frequency breakdowns from multiple trials. Patient forums mix anecdotal reports with official data, creating a confusing blend of verified and unverified claims.
Why does this information vary so much?
Different sources serve different purposes and audiences. The STEP clinical trials (Wilding et al., NEJM, 2021) provide the gold standard data, but even these studies report side effects differently depending on their methodology and duration.
Consumer health sites often simplify complex data for readability. They might say "stomach problems" instead of listing nausea, vomiting, diarrhea, and constipation separately. This isn't necessarily wrong, but it's less precise.
Telehealth platforms face regulatory requirements about how they present side effect information. Some err on the side of comprehensive disclosure, others focus on the most common experiences patients actually report.
What should patients actually know about GLP-1 side effects?
Start with FDA-approved prescribing information, not random health websites. For semaglutide 2.4mg (Wegovy), about 7% of patients stopped treatment due to side effects in clinical trials, compared to 3.1% taking placebo.
Gastrointestinal effects dominate the side effect profile. In the STEP 1 trial, 44% experienced nausea, but this typically decreased over time as patients adjusted to the medication.
Serious side effects like pancreatitis remain rare but require medical attention. The prescribing information lists these clearly with their approximate frequencies. Don't rely on social media or general health websites for complete side effect information when making treatment decisions.